Category Archives: New Jersey Stem Cells

New Jersey, United States Analysis of Stem Cell Assay Market 2022 to 2028, Size, Share, and Trends by Type, Component, Application, Opportunities, Growth Rate, and Regional Forecast

The market for stem cell assays is anticipated to grow at a CAGR of 17.7% from 2022 to 2028 when it is expected to reach USD 4.5 billion from USD 1.9 billion. Increased funding for stem cell research, rising demand for cell-based assays in drug development, collaborations, and agreements among market participants, among other factors, can all be linked to the growth of the stem cell assay market. Typically, the cell-based assay is used to demonstrate the viability, cytotoxicity, senescence, and percentage of the cell. The majority of the time, high-throughput screening formats make use of cell-based assays. To find and build the current technology for secure treatment facilities, many investors and stem cell assay market stockholders have boosted their funding. Additionally, sophisticated cell-based assay treatments are produced as a result of high technology, which makes it simple for researchers, lab technicians, and other medical professionals to make use of cutting-edge equipment to discover various treatments and medications.

Get the Sample Copy of the Stem Cell Assay Market Research 2022 to 2028 @ https://www.infinitybusinessinsights.com/request_sample.php?id=1015054

The COVID-19 epidemic has put more strain on the worlds healthcare systems. As of May 27, 2022, there were 530,469,195 confirmed cases of COVID-19 and 530,469,195 fatalities, according to the World Health Organisation (WHO). The pandemic has had an impact on financing for stem cell assays and cancer research. In reaction to the pandemic, some cancer research institutes have cut back on financing, while others continue to make investments in the field. By utilizing chances present in the research stem cell assays market and creating novel goods to combat the pandemic, prominent businesses participating in the stem cell assays market are changing their long-term and short-term growth strategies. This has had a favorable effect on the markets expansion.

Access the Premium report 2022 with an in-depth TOC (Figures, Tables, Pages).

Venture money has been invested in firms developing stem cell assays. This has accelerated the creation of novel treatments for conditions like cancer. It also provides an endless supply of difficult-to-find cell types, which makes it useful for creating excellent physiological model cells. The development of cutting-edge medical infrastructures and the creation of cutting-edge new technologies have always aided in the expansion of the stem cell assays market sectors for stem cell assays. This implies that several diseases treatment protocols have also evolved. The procedures of treatment approaches in the medical industry have undergone a full transformation as a result of the development of new therapies and generic medicine facilities.

Segmentation

The stem cell assay market is divided into apoptosis, isolation and purification, cell identification, proliferation, differentiation, and viability/cytotoxicity tests based on type. Tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays are other subcategories of the viability/cytotoxicity assays segment. The section of apoptosis assays is further divided into assays for caspase, annexin v, and cell permeability, DNA fragmentation, and mitochondria. In 2021, the viability/cytotoxicity tests segment held the greatest market share. The segments expansion is linked to a rise in the use of tests for toxicology and pharmacology.

The stem cell assay market has been divided into three categories based on technology: microfluidics-based cell trap technologies, microfabricated aided technologies, and others. Cell viability & toxicity tests, cell identification assays, cell proliferation assays, cell apoptosis assays, and others make up the assay section of the market. The application foundation further divides it into five categories: dermatological, cardiovascular, central nervous system, orthopedic & musculoskeletal spine, and others.

Regional analysis

The largest number of market equities in the stem cell assay market sectors are exclusively found in North America. The global market consistently requires the most cutting-edge medical equipment as well as medications that can quickly control disease, according to the rise in rising technology. However, because of the governments sincere efforts, the market has substantially improved in developing nations. The current market expansion is also being boosted by the rise in health awareness. The pandemic has slowed down numerous business platforms economic sectors, but in developing nations, important stockholders and marketers are constantly working to increase production rates to fulfil the wants of the global market. India, China, Japan, and Russia have all contributed significantly to the present market expansion in the Asia-Pacific region.

Key Players

Perkinelmer Inc. Promega Corporation Becton Thermo Fisher Scientific Inc. General Electric Company Dickinson and company Danaher Corporation Merk KGaA Bio-Rad Laboratories Inc.

Click here to Download the full index of the Stem Cell Assay market research report 2022

Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: [emailprotected]Website: https://www.infinitybusinessinsights.com

This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on [emailprotected]

See the article here:
Latest Insights on Stem Cell Assay Market Business Strategies, Acquisitions, Revenue Analysis Share, Forecast to 2028 | by Perkinelmer Inc, Promega...

STATEN ISLAND, N.Y. When Micah Thomas was born, he underwent the mandated newborn screening for sickle cell disease. When the news came back that Micah had the disease, he became one of the roughly 2,000 children born each year with the inherited red blood cell disorder.

Now, at just 9 years old, Micah has been advocating for himself and others like him with sickle cell.

Its why his school, PS 29 in Castleton Corners, recently hosted a dance-a-thon and blood drive for sickle cell.

I was thinking of something everybody in school could do, so maybe a dance-a-thon. And I like dancing at school, he said.

Principal Christine Zapata explained she became principal when Micah was in first grade. She had always discussed hosting an event for sickle cell with Micah and his mother, Monique Faure but Micah had been sick for a better part of his first-grade year, with frequent stays at The Childrens Hospital of Philadelphia. And then the coronavirus (COVID-19) pandemic led to even further delays to host something at school.

Micah stands here with his mother Monique Faure, left, and PS 29 Principal Christine Zapata. (Staten Island Advance/Annalise Knudson)

Micah had to undergo six surgeries, including his most serious the removal of his spleen. But Micah never missed a moment of schoolwork. He was introduced to remote learning even before the coronavirus pandemic, which allowed him to interact with classmates and learn from his teachers while he underwent treatment and recovery.

The support from the school was amazing, said Faure. I think everyone was I mean, they checked on him. We had people come down and check on him. I mean it was amazing. So when Principal Zapata says its a community, it is definitely a community here.

SEVERE SICKLE CELL

Micah is battling HbS beta thalassemia zero, a severe form of sickle cell disease.

It expresses just like sickle cell, even though its sickle cell beta thalassemia, hes treated just like he has full sickle cell, said Faure.

Sickle cell disease means some of Micahs red blood cells are sickle-shaped, while some are round. The sickle cells die early, which causes a constant shortage of red blood cells, and when they travel through small blood vessels, they get stuck and clog the blood flow, according to the Centers for Disease Control and Prevention (CDC).

Micah stands with some of his fellow PS 29 students during the dance-a-thon, which took place last month. (Staten Island Advance/Annalise Knudson)

Some of my blood cells would be shaped like a moon, because that would be the sickle, and the other ones would be shaped like a doughnut, because thats the one that can get through my blood easier, Micah explained. But the ones with the moon, they get less oxygen and they sometimes clog up my blood. I had some stomach pain, and a lot of pain when I was little. I had some arm pain and some pain in my stomach and most times in my spleen.

The condition can cause pain and other serious complications like infection, acute chest syndrome and stroke.

The only therapy approved by the U.S. Food and Drug Administration (FDA) that may be able to cure sickle cell is a bone marrow or stem cell transplant, but those are very risky and can have serious side effects, including death, the CDC stated.

At that point, what we started talking about was the fact that a lot of kids who have sickle cell require blood transfusions, right? Its one of the especially since COVID its something that we are constantly seeing, that theres not enough in the blood supply. Couple that with the fact that sickle cell is pretty prevalent in the United States, said Zapata.

Im excited to dance and everything, Micah said. It makes me feel like sickle cell is getting more support for how it is hurting people, and I just want people to know its helping if you can donate." (Staten Island Advance/Annalise Knudson)

RAISING AWARENESS

Last school year, PS 29 spent a day teaching students about what sickle cell is and how it affects people. The plan to host an event for sickle cell awareness finally came to fruition last month.

On Sept. 30, the school made sure to raise awareness and funds to help those battling sickle cell. Students and staff alike were dressed in red some donning dance-a-thon shirts that read, Brave like Micah.

Throughout the school day, students in each grade made their way to the gymnasium to dance for nearly 30 minutes in the dance-a-thon, led by fifth-grade emcees who volunteered their time.

Im excited to dance and everything, Micah said. It makes me feel like sickle cell is getting more support for how it is hurting people, and I just want people to know its helping if you can donate.

Funds raised from the approximately 300 T-shirts that were sold as part of the dance-a-thon were donated to The Valerie Fund, a non-profit organization that has supported children with cancer and blood disorders since 1976.(Staten Island Advance/Annalise Knudson)

When the fourth-grade class went to the gymnasium, Micah was the first one to start dancing. Students around him joined in, as they danced to popular hits and line dances like the Cha-Cha Slide. Funds raised from the approximately 300 T-shirts that were sold were donated to The Valerie Fund, a non-profit organization that has supported children with cancer and blood disorders since 1976.

The Valerie Funds helps sickle cell awareness, spread the word. So everybody who sees this shirt or they see the videos weve been sending out on stuff, said Micah.

Micah has many friends who are part of The Valerie Fund and struggle with cancer and sickle cell including some who have since died from the diseases, his mother explained.

The school also partnered with the New York Blood Center to host a blood drive.

Anyone can donate to The Valerie Fund at http://www.thevaleriefund.org. Visit http://www.nybc.org/ to donate blood.

PS 29 also partnered with the New York Blood Center to host a blood drive. In this photo, Francie Scherma, a first-grade teacher, donates blood. (Staten Island Advance/Annalise Knudson)

AN ADVOCATE FOR HIMSELF AND OTHERS

Faure said she hopes that she and Micah continue to spread awareness of sickle cell. Micahs treatment is similar to children who have cancer he takes chemo daily. But he still remains upbeat, lively and bubbly.

Zapata noted that the school staff, including the school nurse, know the signs and keep an eye out for Micah if he feels ill at school.

And Micah is very, very good at advocating for himself ,so he lets us know when something is off or something isnt right, said Zapata. He even came to our PTA [parent teacher association] and told our PTA about sickle cell.

Beyond school, Micah has been a voice for those suffering with sickle cell. He has spoken with senators in New York and New Jersey and with other members of Congress to help pass bills for sickle cell, and promote awareness of the disease.

And Micah has big plans for his future he said he hopes to become president of the United States one day.

PS 29 in Castleton Corners held a dance-a-thon and blood drive for sickle cell anemia, which affects a 4th grader at the school, Micah Thomas. (Staten Island Advance/Annalise Knudson)

PS 29 in Castleton Corners held a dance-a-thon and blood drive for sickle cell anemia, which affects a 4th grader at the school, Micah Thomas. (Staten Island Advance/Annalise Knudson)

PS 29 in Castleton Corners held a dance-a-thon and blood drive for sickle cell anemia, which affects a 4th grader at the school, Micah Thomas. (Staten Island Advance/Annalise Knudson)

PS 29 in Castleton Corners held a dance-a-thon and blood drive for sickle cell anemia, which affects a 4th grader at the school, Micah Thomas. (Staten Island Advance/Annalise Knudson)

PS 29 in Castleton Corners held a dance-a-thon and blood drive for sickle cell anemia, which affects a 4th grader at the school, Micah Thomas. (Staten Island Advance/Annalise Knudson)

PS 29 in Castleton Corners held a dance-a-thon and blood drive for sickle cell anemia, which affects a 4th grader at the school, Micah Thomas. (Staten Island Advance/Annalise Knudson)

FOLLOW ANNALISE KNUDSON ON FACEBOOK AND TWITTER.

Continue reading here:
S.I. school hosts dance-a-thon to support 9-year-old student with sickle cell disease - SILive.com

A cord blood bank is a facility which stores umbilical cord blood for future use. Both private and public cord blood banks have developed in response to the potential for cord blood in treating diseases of the blood and immune systems. Public cord blood banks accept donations to be used for anyone in need, and as such function like public blood banks. Traditionally, public cord blood banking has been more widely accepted by the medical community.[1] Private cord blood banks store cord blood solely for potential use by the donor or donor's family. Private banks typically charge around $2,000 for the collection and around $200 a year for storage.[2]

The policy of the American Academy of Pediatrics states that "private storage of cord blood as 'biological insurance' is unwise" unless there is a family member with a current or potential need to undergo a stem cell transplantation.[3][4][5] The American Academy of Pediatrics also notes that the odds of using one's own cord blood is 1 in 200,000[6] while the National Academy of Medicine says that only 14 such procedures have ever been performed.[6] Private storage of one's own cord blood is unlawful in Italy and France, and it is also discouraged in some other European countries. The American Medical Association states "Private banking should be considered in the unusual circumstance when there exists a family predisposition to a condition in which umbilical cord stem cells are therapeutically indicated. However, because of its cost, limited likelihood of use, and inaccessibility to others, private banking should not be recommended to low-risk families."[1] The American Society for Blood and Marrow Transplantation and the American Congress of Obstetricians and Gynecologists also encourage public cord banking and discourage private cord blood banking. Nearly all cord blood transfusions come from public banks, rather than private banks,[2][5] partly because most treatable conditions can't use one's own cord blood.[3][7]

Cord blood contains hematopoietic stem cells (which can differentiate only into blood cells), and should not be confused with embryonic stem cells or pluripotent stem cells, which can differentiate into any cell in the body.[2][3] Cord blood stem cells are blood cell progenitors which can form red blood cells, white blood cells, and platelets. This is why cord blood cells are currently used to treat blood and immune system related genetic diseases, cancers, and blood disorders. Cord blood is also a source of mesenchymal stem cells, which can further be differentiated to form connective tissues, bones and cartilage.[8] On the possibility that cord blood stem cells could be used for other purposes, the World Marrow Donor Association and European Group on Ethics in Science and New Technologies states "The possibility of using ones own cord blood stem cells for regenerative medicine is currently purely hypothetical....It is therefore highly hypothetical that cord blood cells kept for autologous use will be of any value in the future and the legitimacy of commercial cord blood banks for autologous use should be questioned as they sell a service which has presently no real use regarding therapeutic options.[9][10]

In the United States, the Food and Drug Administration regulates cord blood under the category of Human Cells, Tissues, and Cellular and Tissue Based-Products. The Code of Federal Regulations under which the FDA regulates public and private cord blood banks is Title 21 Section 1271.[11] Several states also require accreditation, including New York, New Jersey, and California. Any company not accredited within those states are not legally permitted to collect cord blood from those states, even if the company is based out of state. Potential clients can check the New York accreditation status from the New York Umbilical Cord Blood Banks Licensed to Collect in New York.[12] Both public and private cord blood banks are also eligible for voluntary accreditation with either the American Association of Blood Banks (AABB) or the Foundation for the Accreditation of Cellular Therapy (FACT). Potential clients can check the current accreditation status of laboratories from the AABB list of accredited cord blood laboratories or the FACT search engine of accredited cord blood banks (on their home page).[13] Other countries also have regulations pertaining to cord blood.[14]

Cord blood collection happens after the umbilical cord has been cut and is extracted from the fetal end of the cord, diverting up to 75 +/- 23mL from the neonate. It is usually done within ten minutes of giving birth. Additional stem cells may be collected from the placenta. After the health care provider draws the cord blood from the placental end of the umbilical cord, the placenta is couriered to the stem cell laboratory, where it is processed for additional stem cells. An adequate cord blood collection requires at least 75mL in order to ensure that there will be enough cells to be used for a transplantation. Before the cord blood is stored for later use, it undergoes viral testing, including tests for HIV and Hepatitis B and C, and tissue typing to determine Human Leukocyte Antigen type. It will also be examined for nucleated cell count, cell viability, blood group antigen ABO & Rh blood group system, molecule cluster (CD34), and bacterial and fungal growth.[citation needed]

After the collection, the cord blood unit is shipped to the lab and processed, and then cryopreserved. There are many ways to process a cord blood unit, and there are differing opinions on what the best way is. Some processing methods separate out the red blood cells and remove them, while others keep the red blood cells. However the unit is processed, a cryopreservant is added to the cord blood to allow the cells to survive the cryogenic process. After the unit is slowly cooled to 90C, it can then be added to a liquid nitrogen tank which will keep the cord blood unit frozen at 196C. The slow freezing process is important to keep the cells alive during the freezing process. There is no consensus yet on optimal procedures for these cord blood cells, although many cryopreservation strategies suggest using dimethyl sulfoxide (DMSO), slow or controlled rate cooling, and rapid thawing.[citation needed]

Cord blood stem cells (though usually from donors) are currently used in the treatment of several life-threatening conditions, mainly blood and immune system related genetic diseases, cancers, and blood disorders. The first clinically documented use of cord blood stem cells was in the successful treatment of a six-year-old boy afflicted by Fanconi anemia in 1988. Since then, cord blood has become increasingly recognized as a source of stem cells that can be used in stem cell therapy.[3] Recent studies have shown that cord blood has unique advantages over traditional bone marrow transplantation, particularly in children, and can be life-saving in rare cases where a suitable bone-marrow donor cannot be found. Cord blood stem cells can also be used for siblings and other members of your family who have a matching tissue type. Siblings have a 25% chance of compatibility, and the cord blood may even be a match for parents (50%) and grandparents.[3]

Public cord blood banks function like public blood banks, in that they accept donations from anyone, discard donations that fail to meet various quality control standards, and use national registries to find recipients for their samples. Since patients who need cord blood frequently need more cells than a single collection would have provided, public banks frequently combined multiple samples together when preparing the treatment for a single patient. Unlike bone marrow transplantation, cord blood transplantation doesn't require an exact genetic match, which makes it easier to provide patients samples from unrelated donors.[3] The percentage of public bank donations discarded as medical waste is often cited to be between 60 and 80%. Some of this is due to contamination that occasionally occurs during collection or complications arising from shipping, though this is mostly due to the fact that most cord blood collections fail to collect enough usable cells.[14] Because matches are almost always likely to be better in a public than a private bank, and cord blood from public banks doesn't suffer from the problems it commonly suffers from at private banks (such as potential lower quality control and lower medical usefulness of using a patient's own potentially diseased cord blood), public cord blood banking has been more widely accepted by the medical community.[1] One important obstacle facing public banks is the high cost required to maintain them, which has prevented more than a handful from opening. Because public banks do not charge storage fees, medical centers do not always have the funds required to establish and maintain them.[15]

A recent large study by the journal Pediatrics concluded that almost all cord blood transplants come from public banks:[16]

In the Pediatrics study, transplant specialists who collectively have performed thousands of stem cell transplants for childhood leukemia and other illnesses report that only 50 involved privately banked blood. (Support for public cord-blood banking is widespread in the medical community.) Forty-one cases involved blood used to treat a family member, often a sibling; in 36 of those cases the need for a transplant was known before the cord blood was collected. Only nine cases involved giving cord blood back to the donor, a practice known as autologous transplantation and the chief selling point for private cord-blood banking.

Private banking is typically costly to parents and not covered by insurance. The ability to use the cord blood may also depend on the long-term commercial viability of the enterprise.[7] Accordingly, whether cord blood banking is a worthwhile expenditure for the expectant parent depends in part upon whether the expenditure is offset by the likelihood of ultimately using the cord blood and by the benefits of such use.[7] It is important to ensure the credentials of any potential private bank. In the United States, the Food and Drug Administration regulates cord blood under the category of Human Cells, Tissues, and Cellular and Tissue Based-Products. Since the FDA considers cord blood stored at public banks to be "drugs", but doesn't consider cord blood stored at private banks for use by the donor to be drugs, private banks are held to a lower regulatory standard.[14]

Cord blood transplants require less stringent matching between the tissue types of the donor and patient, known as their human leukocyte antigen (HLA) types. Bone marrow transplants require a complete match on six key antigens, which are measures of graft-versus-host reaction, known as a 6/6 match. Cord blood transplants achieve the same medical success with only a 4/6 match.[14] HLA type is inherited from both parents, so siblings are particularly likely to be a match, and people from the same ethnic heritage are more likely to match. Minority ethnic groups have difficulty finding a perfectly matched transplant donor. Studies have found that allogeneic transplants have a better outcome when the donor and patient are related. The odds that two siblings will have the 6/6 match required for a bone marrow transplant are 25%.[7] The odds that two siblings will have the 4/6 match required for a cord blood transplant are 39%.[citation needed]

The policy of the Society of Obstetricians and Gynaecologists of Canada (SOGC) supports public cord blood banking (similar to the collection and banking of other blood products, i.e. altruistic, anyone can use it), as well as stating that it should only be considered under certain circumstances. The policy of the American Academy of Pediatrics states that "private storage of cord blood as 'biological insurance' is unwise" unless there is a family member with a current or potential need to undergo a stem cell transplantation. Private storage of one's own cord blood is unlawful in Italy and France, and it is also discouraged in some other European countries.[1]

The American Society for Blood and Marrow Transplantation states that public donation of cord blood is encouraged where possible, the probability of using one's own cord blood is very small, and therefore storage of cord blood for personal use is not recommended, and family member banking (collecting and storing cord blood for a family member) is recommended when there is a sibling with a disease that may be treated successfully with an allogeneic transplant.[citation needed]

As of 2007, contracts of the largest cord blood banks do not explicitly state that the cord blood belongs to the donors and child with all the rights and privileges one would reasonably expect from ownership. The ambiguity leaves open future uses not approved by the donors and child. At the majority of private cord blood banking facilities, the mother owns all rights to the cord blood that was banked, until the minor in which the cord blood was taken turns eighteen. At that time the minor has all rights to his or her own banked cord blood.[citation needed]

Concerns have been raised that the current interest in cord blood could cause a perception that cord blood is "unused" by the birth process, thus decreasing the amount of blood which is infused into the child as part of the birth process.[3] The pulsation of the cord pushes blood into the child, and it has been recommended that the cord cease pulsation prior to clamping. With the demand for cord blood increasing, there is a possibility that the cord could be clamped prematurely to preserve even more "extra" cord blood. The American Academy of Pediatricians notes: "if cord clamping is done too soon after birth, the infant may be deprived of a placental blood transfusion, resulting in lower blood volume and increased risk for anemia."[3]

Using one's own cord blood cells might not be wise or effective, especially in cases of childhood cancers and leukemia. Children who develop an immunological disorder often are unable to use their own cord blood for transplant because the blood also contains the same genetic defect.[9]

Additional issues include the possible contamination of the cord blood unit with the same cancer diagnosed later in life; for example, abnormal cells have been detected in filters containing newborn blood of children who were not diagnosed with acute leukemia until the age of 2 to 6 years. The high relapse rates after autologous or syngeneic transplant and the benefit of a graft-vs.-leukemia effect of an allogeneic transplant suggest that autologous cord blood would not be the ideal source of stem cells for patients with leukemia needing a transplant.[citation needed]

The public in the United States has a general awareness of embryonic stem cells because of the stem cell controversy. However, cord blood stem cells (hematopoietic stem cells) are not embryonic stem cells (pluripotent stem cells).[2][3]

See original here:
Cord blood bank - Wikipedia

New Jersey, United States, Sept. 4, 2022 /DigitalJournal/ Cellular reprogramming is the process of reverting mature and specialized cells into induced pluripotent stem cells. Reprogramming also refers to the erasure and resetting epigenetic marks during mammalian germ cell development. Stem cells are studied and developed in treatments for various ailments using cell reprogramming methods, as a method of replenishing cells damaged by disease. These cells are created from somatic cells, such as blood or skin cells, that have undergone genetic reprogramming to resemble embryonic stem cells to produce an endless supply of a wide variety of human cells for therapeutic purposes.

The Cell Reprogramming Market research report provides all the information related to the industry. It gives the markets outlook by giving authentic data to its client which helps to make essential decisions. It gives an overview of the market which includes its definition, applications and developments, and manufacturing technology. This Cell Reprogramming market research report tracks all the recent developments and innovations in the market. It gives the data regarding the obstacles while establishing the business and guides to overcome the upcoming challenges and obstacles.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

https://a2zmarketresearch.com/sample-request

Competitive landscape:

This Cell Reprogramming research report throws light on the major market players thriving in the market; it tracks their business strategies, financial status, and upcoming products.

Some of the Top companies Influencing this Market include:Allele Biotechnology, ALSTEM, Applied Biological Materials, Axol Bioscience, Creative Bioarray, DefiniGEN, Fujifilm Cellular Dynamics, Lonza, Mogrify, REPROCELL, Stemnovate, Thermo Fisher Scientific

Market Scenario:

Firstly, this Cell Reprogramming research report introduces the market by providing an overview that includes definitions, applications, product launches, developments, challenges, and regions. The market is forecasted to reveal strong development by driven consumption in various markets. An analysis of the current market designs and other basic characteristics is provided in the Cell Reprogramming report.

Regional Coverage:

The region-wise coverage of the market is mentioned in the report, mainly focusing on the regions:

Segmentation Analysis of the market

The market is segmented based on the type, product, end users, raw materials, etc. the segmentation helps to deliver a precise explanation of the market

Market Segmentation: By Type

Sendai Virus-based ReprogrammingmRNA ReprogrammingEpisomal ReprogrammingOthers

Market Segmentation: By Application

Research & Academic InstitutesBiotechnology & Pharmaceutical CompaniesHospitals & Clinics

For Any Query or Customization: https://a2zmarketresearch.com/ask-for-customization

An assessment of the market attractiveness about the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations, new developments, marketing strategies, branding techniques, and products of the key participants in the global Cell Reprogramming market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.

This report aims to provide:

Table of Contents

Global Cell Reprogramming Market Research Report 2022 2029

Chapter 1 Cell Reprogramming Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cell Reprogramming Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4157

Follow this link:
Cell Reprogramming Market is Expected to Record the Massive Growth, with Prominent Key Players Allele Biotechnology, ALSTEM, Applied Biological...

NIJMEGEN, Netherlands, Sept. 6, 2022 /PRNewswire/ -- Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the cancer micro-environment today announces the final close of its Series A financing, with total funds raised of 17.3 million. The funds will be used to complete development and commercialise the Company's novel lead PlecoidProduct, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML).

The investments include 3.6 million in new equity committed by Oost NL and a select number of private investors, 5m in government funding from the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO), and 8.7 million in equity and R&D project financing from Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) previously announced in late 2021.

In total, at final close, the round exceeds the Company's goal of 15 million. It provides sufficient funds to complete the development of PTX-061's regulatory dossier in AML and to be ready for submission to the FDA and EMA as early as 2024, and to accelerate preclinical work in other indicationssuch as Small-Cell Lung Cancer (SCLC).

Pleco's novel Plecoidtherapies are patented, innovative treatments that include chelating agents with different characteristics, that have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell, thereby improving the effectiveness of existing chemotherapy.

Whilst AML is a relatively rare disease, the effectiveness of current chemotherapy may be limited because the leukaemia cells can become resistant to it over time. The majority of patients will relapse, even after an initial successful treatment. Relapses carry a poor prognosis; most patients no longer respond to treatment and die from anaemia, infection, or multiorgan failure.Worldwide the incidence of AML is estimated to be 350,000 cases per year (4.7 cases per 100,000 population)1. In the US, there was an estimated 20,050 new cases of AML in 2022 and 11,540 deaths2.

Pleco's technology provides a platform for the development of a pipeline of therapies. In addition to PTX-061 for AML, the current pipeline includes additional candidates in preclinical testing for the treatment of other rare diseases such as SCLC.

Ivo Timmermans, Chief Executive Officer of Pleco Therapeutics, commented:"We are delighted to have secured the funds needed to progress our lead drug candidate through development, for the treatment of AML, a blood cancer that carries a very poor prognosis. We welcome our new shareholders and are grateful for the support from Oost NL and RVO."

Pleco's funding from the RVO is the maximum granted under its Innovation Credit scheme that helps entrepreneurs with promising and challenging innovations with excellent market perspective. It provides special funding, a national and internationalnetwork, and personal advice for innovative start-ups.

Pleco recently announced its expansion, with the incorporation of its subsidiary, Pleco Therapeutics USA, Inc., and the appointment of Michael Stalhamer as its President and first US-based employee. Mr Stalhamer also serves on the global leadership team as Vice President (VP) Product Development and Regulatory Affairs.

About Acute Myeloid Leukaemia (AML)

AML is a type of heterogenous haematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including lymph nodes, spleen, central nervous system, and testicles. AML is an orphan disease and is the most common type of acute leukaemia in adults and is primarily a disease of the adulthood; the median age of newly diagnosed AML patients is around 67 years. Worldwide the incidence of AML is estimated to be 350,000 cases per year (4.7 cases per 100,000 population, Globocan). In the US, there was an estimated 20,050 new cases of AML in 2022 and 11,540 deaths. Additionally, AML is more common in males. AML can arise de novo or secondarily either due to the progression of other diseases or due to treatment with cytotoxic agents.

About Pleco Therapeutics

Pleco Therapeutics is a clinical stage specialty biopharmaceutical company which aims to extend the life span and enhance the quality of life of patients through its novel Plecoid therapies that have been designed to dramatically increase the effectiveness of current cancer treatments. Its novel Plecoid therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell, thereby improving the effectiveness of existing chemotherapy. A private company, Pleco is headquartered in Nijmegen, the Netherlands, with a U.S. subsidiary, Pleco Therapeutics USA Inc, based in Newark, New Jersey.

For more information visit http://www.plecotherapeutics.com. Follow us on LinkedIn and Twitter

[1] Worldwide AML incidence cases,Globocan registry[2]Cancer Stat Facts: Leukemia Acute Myeloid Leukemia (AML), SEER, 2022

For more information, please contact:MediaSue Charles, Charles Consultants [emailprotected] +44 (0)7968 726585

SOURCE Pleco Therapeutics

Original post:
Pleco Therapeutics Announces Final Close of its Series A Financing Raising 17.3m to Progress its Novel Plecoid Product in Acute Myeloid Leukaemia to...

- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half of 2022 -

- Ended second quarter 2022 with cash, cash equivalents, and investments of $429.4; Expected cash runway into 2025 -

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2022.

We are excited about our recent IND submission for our lead candidate, CNTY-101, and pending FDA clearance, are looking forward to initiating the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma, said Lalo Flores, Chief Executive Officer, Century Therapeutics. We continue to make steady progress in building a best-in-class allogeneic cell therapy platform and achieved a key milestone this quarter in establishing the iNK 3.0 Common Progenitor, which we believe will accelerate new candidate selection. Additionally, we look forward to providing updates on our gamma delta iT platform and other program advancements in the coming months.

Business Highlights

The Company

preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, during a poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting held on May 16-19, 2022 in Washington, D.C. A copy of the presentation is available in the Posters section of Centurys website. During a Research and Development Event in June, Centurys management team discussed CNTY-103, the Companys first solid tumor candidate for glioblastoma, the establishment of the Common Progenitor iNK 3.0, and progress on the Companys next-generation iPSC-based cell therapy platform. Century expects to submit an Investigational New Drug (IND) application for CNTY-103 in 2024. The Companys current Good Manufacturing Practice (cGMP) manufacturing facility in Branchburg, New Jersey is operational and undergoing qualification.Century was added to the Russell Microcap Index in June 2022.

Subsequent Events and Upcoming Milestones

Following the recent submission of the IND application for CNTY-101, the Company remains on track to initiate its Phase 1 ELiPSE-1 clinical trial in the second half of 2022, subject to U.S. Food and Drug Administration (FDA) clearance of the application. ELiPSE-1 will assess CNTY-101 in patients with relapsed/refractory CD19 positive aggressive lymphoma or indolent lymphoma after at least two prior lines of therapy, including patients who have received prior CAR-T cell therapy.

Second Quarter 2022 Financial Results

Cash Position:Cash, cash equivalents, and investments were $429.4 million as of June 30, 2022, as compared to $358.8 million as of December 31, 2021. Net cash provided by operations was $61.2 million for the six months ended June 30, 2022 (which includes deferred revenue from the Bristol-Myers Squibb (BMS) collaboration of $120.7M) compared to net cash used in operations of $40.7 million for the six months ended June 30, 2021.Collaboration Revenue: Collaboration revenue was $1.4 million for the three months ended June 30, 2022, generated through the Companys collaboration, option and license agreement with BMS.Research and Development (R&D) expenses: R&D expenses were $24.5 million for the three months ended June 30, 2022, compared to $18.9 million for the same period in 2021. The increase in R&D expenses was primarily due to an increase in personnel expenses related to increased headcount to expand the Companys R&D capabilities, costs for pre-clinical studies, costs for laboratory supplies and facility costs, offset by a decrease in collaboration expenses with FUJIFILM Cellular Dynamics, Inc. (FCDI) as the scope of work with FCDI has narrowed down to primarily manufacturing CNTY-101 clinical supply. General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the three months ended June 30, 2022, compared to $4.1 million for the same period in 2021. The increase was primarily due to an increase in employee headcount, an increase in directors and officers insurance expense and an increase in the Companys professional fees as a result of expanded operations to support the Companys infrastructure as well as additional costs to operate as a public company, and increased information technology and facility costs. Net loss: Net loss was $31.0 million for the three months ended June 30, 2022, compared to $23.3 million for the same period in 2021.

Financial Guidance

The Company expects full year GAAP Operating Expenses to be between $155 million and $165 million including non-cash stock-based compensation expense of $10 million to $15 million. The Company expects its cash, cash equivalents, and investments will support operations into 2025.

About Century Therapeutics

Century Therapeutics, Inc. (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit https://www.centurytx.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash, financial resources, and estimated expenses, our clinical development plans and timelines, and the development of our U.S. manufacturing facility are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will, should, expect, plan, aim, seek, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, forecast, potential or continue or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to obtain FDA acceptance for our IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the Risk Factors section of our most recent filings with the Securities and Exchange Commission and available at http://www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Company: Elizabeth Krutoholow investor.relations@centurytx.com

Investors: Melissa Forst/Maghan Meyers century@argotpartners.com

Media: Joshua R. Mansbach century@argotpartners.com

Go here to read the rest:
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - KULR-TV

New Jersey, United States This in-detail Cell ExpansionMarket analysis presents a review of crucial industries, which are greatly helping to impel market growth. This market study report further depicts mergers, acquisitions amid startups, strategies, product launching, and collaborations followed by industry players of the market. Industry players in the market take more efforts to go with new technology to get a competitive advantage over the cut-throat competition of the market. In order to retain their position in the market, most of organizations are recently following new developments, expansions, long-term contracts, and product developments. It further covers how COVID-19 affected a number of industries. It not affected the industries but also affected important parts of the society such as public transportation, huge gatherings, and a few mediums of travel.

Cell Expansion market research plays an important role in take business-related decisions. Making data-driven decisions is difficult due to the fast-shifting market landscape. But in this regard, it hugely helps and makes several different crucial business operations smooth around an industry. It not only predicts the business growth and market size but also focuses on gathering precise data and qualitative evaluations about the business direction. This Cell Expansion market report does an in-detail study of the volatile market environment to provide key players with significant data about key developments and market tactics. It greatly helps business players in driving important decision-making.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=23777

Key Players Mentioned in the Cell Expansion Market Research Report:

Thermo Fisher Scientific, Inc., GE Healthcare (A Wholly Owned Subsidiary of General Electric Company), Lonza Group Ltd., Becton, Dickinson and Company, Corning, Inc., Merck KGAA, Beckman Coulter, Inc. (Subsidiary of Danaher Corporation), MiltenyiBiotec, Stemcell Technologies, Terumo BCT, Inc. (A Subsidiary of Terumo Corporation).

Cell ExpansionMarket Segmentation:

Cell Expansion Market, By Product

Consumables Instruments Others

Cell Expansion Market, By Cell Type

Human Cells Animal Cells

Cell Expansion Market, By Application

Regenerative Medicine and Stem Cell Research Cancer and Cell-Based Research Others

Cell Expansion Market, By End-user

Research Institutes Biotechnology and Biopharmaceutical Companies Cell Banks Other End Users

This Cell Expansion market report assists a number of investors, shareholders as well as enterprises in understanding the tough areas of marketing ideas, technical development, key issues, and systematic analysis in order to accomplish long-term competitive gain in the industry. It goes on to talk about basic market facets along with market drivers, restraints, existing problems, forthcoming opportunities, and forecasts. This Cell Expansion market survey depicts a few exact customer insights in order to build technology strategies to make investment useful. It makes use of both primary and secondary methods to offer wide-ranging industry data to help out you in making business choices and introducing new items to the market.

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=23777

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Cell Expansion market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Cell Expansion market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Cell Expansion market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Cell Expansion market by application, it gives a study on the consumption in the Cell Expansion market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Cell Expansion market are profiled in this section. The analysts have provided information about their recent developments in the Cell Expansion market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Cell Expansion market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Cell Expansion market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Cell Expansion market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/cell-expansion-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read this article:
Cell Expansion Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 Shanghaiist - Shanghaiist

JERSEY CITY, N.J., July 20, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global 3D Bioprinting for Tissue and Organ Regeneration MarketBy Type (Magnetic 3D Bioprinting, Laser-assisted Bioprinting, Inkjet 3D Bioprinting, and Microextrusion 3D Bioprinting), Application (Clinical Applications, Research Applications, Drug and Medical Research, and Others) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

InsightAce Analytic Pvt. Ltd. Logo

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1336

According to the latest research by InsightAce Analytic, the global 3D bioprinting for tissue and organ regeneration market is expected to reach US$ 424.36 million by 2030, with a CAGR of 15.8% during the forecast period of 2022-2030.

Bioprinting in three dimensions, a process of biomaterials production based on additive manufacturing, is a new and productive strategy in the medical and pharmaceutical areas. This technique has been a pioneer in making artificial multicellular tissues/organs due to its capacity to generate regenerative tissues and organs. 3D printing is a promising method for fabricating implants because it permits the construction of implants with complicated internal structures and high resolution using medical data sets. Pre-bioprinting, Bioprinting, and post-bioprinting are the three primary processes that make up the 3D bioprinting process. The output construct from 3D Bioprinting keeps its cell viability and function, making it suitable for research and development (R&D) in a variety of medical fields.

Increased focus on R&D investment and technological improvements for producing customized products are only a few of the factors anticipated to show considerable growth of the global 3D Bioprinting for Tissue and Organ Regeneration Market over the forecast period. Increased use of 3D printing in aesthetic procedures and advancements in 3D Bioprinting is also anticipated to support the growth of the 3D Bioprinting for the Tissue and Organ Regeneration market throughout the course of the forecast period. Additionally, there is a significant need for organ transplants among patients and medical professionals, and the newly developed 3D bioprinting technologies have a promising future in bridging this gap. Stem cell research is likely to increase, and 3D bioprinting awareness is predicted to rise, providing lucrative potential for industry participants.

Story continues

A number of pharmaceutical firms are rapidly utilizing 3D bioprinting goods and technologies to find and develop new drugs. 3D Bioprinting enables pharmaceutical companies to test medications more affordably and safely than the conventional drug testing procedure. The use of 3D Bioprinting has increased as people's understanding of this technology has grown, particularly in the cosmetics sector. However, During the forecast period, strict government regulations, high treatment costs, and difficulty obtaining reimbursements and coverage for these therapies are anticipated to restrain the worldwide market growth.

In the forecast period, North America will hold the most significant market share for 3D Bioprinting for the Tissue and Organ Regeneration Market globally. North America has a sizable portion of the global market for 3D Bioprinting for the Tissue and Organ Regeneration Market due to large-scale public and private investments in the development of these technologies, their rapid adoption rates, and the presence of prominent industry participants in the area. A large number of clinical trials in North America may be attributed to the presence of research institutes engaged in the discovery of novel therapies, the presence of leading market participants with significant U.S. presence, and the accessibility of cutting-edge technologies.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1336

Major market players operating in the 3D Bioprinting for Tissue and Organ Regeneration market include BIOLIFE4D, Organovo, Celllink, Aspect Biosystems, Cyfuse Biomedical, TeVido Biodevices, Digilab, Advanced Solutions Life Sciences, TRS Tissue Regeneration Systems, Nscrypt, Inc, EnvisionTEC, MedPrin, Nano3D Sciences, Rokit, Cellbricks, REGEMAT 3D, Allevi, Poietis, and T&R BIOFA.

Key developments in the market:

In March 2022, CELLINK, a BICO Company, introduced the BIO CELLX, a revolutionary technology that automates 3D cell culture operations using pre-validated protocols. The BIO CELLX expands on CELLINK's impressive bioprinting portfolio by combining tried-and-true technologies, such as the patented Clean Chamber, with novel approaches for high-precision dispensing, automatic nozzle priming, and effortless mixing of hydrogels and cells to produce a system for repeatable and high throughput model generation.

In April 2022, Aspect Biosystems and the global diabetes research and advocacy group JDRF announced a new relationship. As part of the agreement, JDRF has pledged to support Aspect Biosystems' efforts to develop innovative 3D bioprinted tissues for treating type 1 diabetes.

In Jan 2022, Sciperio, the research arm of nScrypt, was given a U.S. patent for a 3D-printed device, circuitry, and sensors for a tailored electronic therapeutic training device. The previous year, nScrypt continued to advance its microdispensing technique by attaining 6-axis 3D printing with their 3Dn-Axis FiT 3D printer.

In March 2021, Poietis announced that their laser-assisted 3D bioprinting approach has been granted a third patent. The business has recently invented a 4D bioprinting process in which tissue self-organization is programmed by CAD-designed starting tissue architecture. Thus, the functioning of the 3D bioprinted tissues is enhanced.

In April 2019, Orgenesis Inc. stated that it has entered into a partnership agreement with Digilab Inc. to create a technique and system for automating the synthesis of three-dimensional living cellular structures and tissues. Under the terms of the Agreement, Orgenesis had the exclusive right to co-develop the method and systems necessary for its therapeutic cooperation initiatives, as well as the right to utilize, market, and distribute the novel cell printer systems and related goods.

Market Segments

Global 3D Bioprinting for Tissue and Organ Regeneration Market, by Type, 2022-2030 (Value US$ Mn)

Global 3D Bioprinting for Tissue and Organ Regeneration Market, by Application, 2022-2030 (Value US$ Mn)

Global 3D Bioprinting for Tissue and Organ Regeneration Market, by Region, 2022-2030 (Value US$ Mn)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

North America 3D Bioprinting for Tissue and Organ Regeneration Market, by Country, 2022-2030 (Value US$ Mn)

Europe 3D Bioprinting for Tissue and Organ Regeneration Market, by Country, 2022-2030 (Value US$ Mn)

Germany

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific 3D Bioprinting for Tissue and Organ Regeneration Market, by Country, 2022-2030 (Value US$ Mn)

India

China

Japan

South Korea

Australia & New Zealand

Latin America 3D Bioprinting for Tissue and Organ Regeneration Market, by Country, 2022-2030 (Value US$ Mn)

Brazil

Mexico

Rest of Latin America

Middle East & Africa 3D Bioprinting for Tissue and Organ Regeneration Market, by Country, 2022-2030 (Value US$ Mn)

For More Customization @ https://www.insightaceanalytic.com/customisation/1336

Why should buy this report:

To receive a comprehensive analysis of the prospects for the global 3D bioprinting for tissue and organ regeneration market

To receive an industry overview and future trends of the 3D bioprinting for tissue and organ regeneration market

To analyze the 3D bioprinting for tissue and organ regeneration market drivers and challenges

To get information on the 3d bioprinting for tissue and organ regeneration market size (Value US$ Mn) forecast to 2030

Major investments, mergers & acquisitions in the 3D bioprinting for tissue and organ regeneration market industry

Other Related Reports Published by InsightAce Analytic:

Global Cardiovascular And Soft Tissue Repair Patch Market

Global 3D Printed Medical Sensor and Biosensor Market

Global Biospecimen Contract Research Services Market

Global Cell & Gene Therapy Raw Material Testing Market

Global iPSCs Manufacturing Services Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Logo - https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

Contact Us:InsightAce Analytic Pvt. Ltd.Tel.: +1 551 226 6109Email: info@insightaceanalytic.comSite Visit:www.insightaceanalytic.comFollow Us on LinkedIn @bit.ly/2tBXsgSFollow Us OnFacebook@bit.ly/2H9jnDZ

Cision

View original content:https://www.prnewswire.com/news-releases/3d-bioprinting-for-tissue-and-organ-regeneration-market-worth-424-3-million-by-2030---exclusive-report-by-insightace-analytic-301590006.html

SOURCE InsightAce Analytic Pvt. Ltd.

Read the original:
3D Bioprinting for Tissue and Organ Regeneration Market worth $424.3 Million by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance

Jennifer Nsenkyire had been cured of sickle cell disease via stem cells.

After a lifetime of sickness, Jennifer Nsenkyire was cured of two separate and debilitating diseases with a stem cell transplant, and those who knew her rejoiced.

That included family in West Africa, where she was born, and the friends and support system she found in Fredericksburg, her second home. After the transplant freed her from the pain shed experienced since a toddler with sickle cell disease a hereditary blood disorder Nsenkyire became active with the Fredericksburg Area Sickle Cell Association, or FASCA. She worked to educate others about the ailment and how those with it could find help and support.

She was always so very, very kind and helpful to other clients, those who continued to suffer with the disease and are not eligible for transplant because of age, said Janice Davies, FASCAs co-founder. She had a presence that really resonated with everybody.

Nsenkyire shared her medical story with others through programs and videos to the point National Institutes of Health officials described her experience as one in a million, said FASCA member Myra Dicks. Nsenkyire also had battled multiple sclerosis until her transplant and, as a child, dealt with osteomyelitis, a bone infection that temporarily left her unable to walk.

People are also reading

Then, in the strange way life sometimes works, it was yet another disease that took the life of the soft-spoken 49-year-old from Ghana. Nsenkyire contracted COVID-19 earlier this year and died on April 25.

The most ironic thing is she had been through all of that, and then to have something like COVID take her away, it was hard, Davies said.

It was heartbreaking, Dicks added.

As is customary in Ghana, family members held several celebrations of her life, culminating with a memorial service at the NIHs offices in Bethesda, Maryland, in late June. While those who knew her mourn her loss, they also celebrate the mark she left on the world.

She had this infectious smile that lit up the room when she walked in, you all know that, Fran Boyle said to the crowd gathered at Strong Tower Church for her funeral service.

Boyle was Nsenkyires host mother when she first arrived in 1995 to attend George Mason University in Fairfax. Boyle wanted to host international students, and Nsenkyire wanted to be paired with a Christian family, and Boyle said she loved her immediately.

There were plenty of ups and downs with her health, Boyle said, as the sickle cell disease caused swelling in her arms and legs, along with numerous pain crises. Thats when red blood cells, which have turned from their normal round shape to something resembling sickles, block blood flow through tiny vessels to the chest, abdomen and joints. A crisis causes varying intensities of pain that can last for hours or days.

Boyle recalled walking the hospital floors with Nsenkyires parents, Edward and Rose Nsenkyire, who divided their time between continents until they eventually settled in the United States, and her sisters, Pamela Asamoah and Clara Nsenkyire, who both live in the Fredericksburg area. Nsenkyire also has a brother, Dennis, in New Jersey.

Shed been through so much, said her sister, Clara Nsenkyire. It was crisis upon crisis.

As Jennifer Nsenkyire was treated at NIH, medical officials mentioned a transplant, using stem cells from family members that most closely matched her own. When the family gathered with NIH doctors for a consultation, they heard about potential side effects and werent sure which way to go, her sister said.

She was so brave, Clara Nsenkyire said. She said, Even if it doesnt help me, it will help somebody else.

Plus, Jennifer Nsenkyire wished she could live one day without the pain of sickle cell disease, her sister said. She opted for the transplant, using her mothers stem cells, and it was successful. After the 2010 operation, she was free of both sickle cell and MS, and she recorded her thoughts and experiences, both in YouTube videos and books she wrote.

She longed for a cure and for others to be free of pain as she was.

A cure would be, being able to live life with no pain, being able to live a productive life, being able to shake off the stigma that people have about sickle cell disease, she said in a video. Being able to live fearlessly, being able to live a normal life, thats all we all want at the end of the day. Its time to rewrite the story of sickle cell. Add your voice.

That she did, said Pastor Jeffrey Smith of Strong Tower Church, who said hers was a life that was lived so well and so elegantly before us.

In spite of the challenges and difficulties she experienced, she always had this strength of spirit, this tenacity, this perseverance, he said. She had this ongoing optimism and faith that would never die.

See the rest here:
After conquering sickle cell and multiple sclerosis, it was COVID-19 that claimed her - Lynchburg News and Advance

New Jersey, United States-Stem Cell Therapy Market 2022 2030, Size, Share, and Trends Analysis Research Report Segmented with Type, Component, Application, Region, and Forecast

The mesenchymal stem cells infiltrate and incorporate into different organs, fix cardiovascular, lung, and spinal line wounds, and work on the condition of immune system infections, liver, and bone and ligament illnesses. Stem cells are a powerful instrument for the treatment of diseases brought about by irritation, insusceptible system disappointment, and, or tissue degeneration.

The drivers answerable for the development of the worldwide stem cell therapy market are the expanded occurrence of ongoing illnesses, ascend in GMP-confirmation endorsements for cell therapy creation offices, development of biotechnology area, and ascend in clinical preliminaries for stem-cell-based treatments. Notwithstanding, factors that are supposed to control the market development are the ascent in the expense of stem cell-based research, and the dangers looked at while going through stem cell therapy, and the accessibility of options.

Receive the Sample Report of Stem Cell Therapy Market Research Insights 2022 to 2030 @ https://www.infinitybusinessinsights.com/request_sample.php?id=817266

Division segment

In view of type, the worldwide stem cell therapy market is extensively divided into allogeneic stem cell therapy and autologous stem cell therapy. In 2022, the allogeneic portion represented the biggest portion of the stem cell therapy market. The development of the allogeneic portion is credited to the simplicity of assembling and creation processes and the rising accessibility of novel stem cell items across significant geologies.

In light of restorative application, the worldwide stem cell therapy market is divided into outer muscle problems, wounds and wounds, cardiovascular illnesses, medical procedures, provocative and immune system sicknesses, neurological problems, and other remedial applications (which incorporate visual infections, fat misfortune, and fringe blood vessel infections). The neurological problems portion is supposed to develop at the most noteworthy CAGR during the gauge time frame inferable from the rising commonness of neurological problems and the significant expense of therapy.

Regional Analysis

Topographically, the stem cell therapy market is divided into North America, Europe, Asia Pacific, RoW. In 2022, North America represented the biggest portion of the stem cell therapy market, trailed by Asia Pacific and Europe. The huge portion of this territorial fragment in the worldwide market can fundamentally be ascribed. The enormous portion of North America in the worldwide market can be credited to the rising public-private financing and examination awards for creating safe and compelling stem cell therapy items and the developing number of clinical preliminaries.

Competitive Analysis

Central participants in the stem cell therapy market incorporate Smith and Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), and NuVasive, Inc. (US).

The following are some of the reasons why you should take a Stem Cell Therapy market report:

Explore the Full Index of the Stem Cell Therapy Market Research Report 2022

Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: [emailprotected]Website: https://www.infinitybusinessinsights.com

Go here to see the original:
Stem Cell Therapy Market to Observe Exponential Growth By 2022 to 2030 | Smith, Nephew (UK), MEDIPOST Co Ltd. (South Korea) - Digital Journal